# LNP

CSPC Pharma Pivots to Next-Gen Cell Therapy with mRNA-Based CAR-T Clinical Approval

CSPC Pharmaceutical Group has received Chinese regulatory approval to begin clinical trials for SYS6063, a dual-target CAR-T therapy delivered via mRNA-LNP technology. This milestone reflects a strategic shift toward non-viral delivery systems that could make advanced cancer treatments more scalable and cost-effective.